

A Cancer Drug Resistance Company

Swiss Biotech Day

Basel, April 24-25, 2023

Mads Aaboe Jensen, PhD
VP Business Development & Innovation



Disclaimer

This presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the "Presentation"), has been prepared by Scandion Oncology A/S ("Scandion Oncology" or the "Company"), to be used solely for a company presentation. The information contained in the Presentation is provided solely for this purpose.


This Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The Company has not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America.

Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No representation or warranty, express or implied, is made by the Company as to the accuracy, completeness or verification of any information contained in this Presentation. The Company has not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general publications.

Statements in this Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Past performance does not guarantee or predict future performance. Moreover, the Company does not – to the extent this is not required by law - undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this Presentation.

This Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Danish law. The courts of Denmark, with the District Court of Copenhagen as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Presentation or related matters.

How cancer cells become resistant to cancer drugs...



Multiple mechanisms identified

- drug target mutations
- oncogene/tumor-suppressor deregulation
- activation of pathways blocking drug action
- increased DNA damage repair
- overexpression of drug efflux pumps (ABC transporters)
- induction of cell adhesion-mediated drug resistance

SCO-101 is a selective inhibitor of ABCG2 that has been linked to resistance towards many cancer drugs

... causing up to 90% of cancer deaths

Close to 10 million people globally are dying from cancer every year

Likely up to 90% of cancer deaths are due to drug resistant cancer cells¹

40-50% of drugs in development fail due to lack of efficacy² – A big proportion of these failures are likely caused by undetected drug resistance

1 Bukowski et al, 2020, 2 Harrison et al, 2016

A clinical stage biotech company...

Our mission

To bring new medicines to patients in order to overcome cancer drug resistance and improve lives for cancer patients and their families



2 Clinical Programs

1 Phase II, 1 Phase Ib



Pipeline

SCO-101, SCO-201, 800 analogues



Cancer Indications

Colorectal, pancreatic and hematology



Experience

>100 years collective experience in medical oncology and pharmaceutical development



People

10 employees
Office in Copenhagen, Denmark



Listed Stock Exchange

Nasdaq First North Stockholm



Cash position of DKK 78m

December 31, 2022



8,195 Shareholders

December 31, 2022

... run by a seasoned leadership team



Francois Martelet

Chief Executive Officer

- Doctorate in Medicine
- Master's Degree in Business
- Advanced Management Program, INSEAD
- Executive education finance & management programs, Harvard Business School
- +30 years experience in the global life science industry
- Leadership positions in several pharmaceutical Cos and CEO and chairman of a number of US and European biotech Cos



Johnny Stilou

Chief Financial Officer


- MSc in Business Economics and Auditing
- Executive Management Program, INSEAD
- Has held numerous positions as CFO within the biotech and pharmaceutical industry



Alfredo Zurlo

Chief Medical Officer

- Medical Doctor with specialization in Oncology and Radiation Therapy
- +20 years' experience in clinical development and medical affairs
- Led the launch of bevacizumab (Avastin) for Roche in Europe and rest of the world for the colorectal cancer indication
- Served as CMO in biotech Cos



Jan Stenvang

Chief Scientific Officer & co-founder

- Ph.D. in Molecular and Cellular Biology
- +20 years of experience in cancer research
- Specialized in translational cancer research particularly focusing on drug resistance and biomarker identification

Developing first-in-class medicines for personalized therapy targeting cancer drug resistance...

Program	Compound	Indication	Discovery / Pre-clinical	Phase I	Phase II	Phase III
CORIST	SCO-101	Colorectal cancer	SCO-101 + FOLFIRI		Part 3 interim results in H2 (Q3), 2023	
PANTAX	SCO-101	Pancreatic cancer	SCO-101 + nab-paclitaxel and gemcitabine		Topline data in H1, 2023	
Hematology	SCO-101	AML	Pre-clinical data in H2, 2023			
201	SCO-201	Solid tumors	Currently on hold			

... with currently two ongoing clinical trials in colorectal and pancreatic cancer...

CORIST



Multi-center, open label, dose escalation, Phase II study of SCO-101 in combination with FOLFIRI



Patients with metastatic colorectal cancer with acquired resistance to FOLFIRI (last line of treatment)



Both dose-finding and efficacy assessment parts

PANTAX



Open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel




Patients with unresectable or metastatic pancreatic cancer who are to be treated with gemcitabine and nab-paclitaxel



Dose-finding trial

... and entering hematology in Acute Myeloid Leukemia (AML)




Cazzola et al, NEJM 2020

¹ Damiani et al 2010 (Leuk Res), ²Tiribelli et al 2011 (Cancer), ³Benderra et al 2004 (Clin Cancer Res), ⁴Damiani et al 2006 (Haematologica)

- A major problem in the treatment of AML is relapse after achieving remission, disease relapse arises from a few therapy-resistant cells
- ABCG2 expression is present in 35-50% of AML cells and associated to clinical outcome^{1,2,3,4}. ABCG2 is an efflux-pump that has been linked to drug resistance and cancer stem cell properties in many cancers
- Initial pre-clinical data supports that inhibition of ABCG2 enhances the effect of AML drugs in ABCG2 over-expressing cancer cells
- As drug resistance is a major unsolved problem for the treatment of AML, we believe it will be clinical beneficial to specifically target ABCG2 in combination with standard-of-care treatment
- Scandion is the only company that has a specific ABCG2 inhibitor (SCO-101) in clinical stage that doesn't broadly target other efflux pumps

AML-strategy: Three synergistic tracks to generate pre-clinical data




Our strategic priorities 2023/24 with multiple shots on goal...



**Continue CORIST and PANTAX
and obtain read outs according
to plan**




**Define next steps for both
mCRC and pancreatic cancer**



**Plan and conduct pre-clinical
activities in hematology/AML**

... and several expected events in 2023

H1 2023



PANTAX

Topline data from
phase Ib



H2 (Q3) 2023



CORIST

Topline data from
part 3

H2 2023



Hematology/AML

Pre-clinical data

Financing secured into
2024

Scandion is one of the first movers in cancer drug resistance

We are one of the first movers in cancer drug resistance

- We are potentially first-in-class, targeting a huge market

High medical need in an established market

- 10M cancer-related deaths annually
- SCO-101 has broad potential

Solid financial position

- Current cash funds operations into 2024

Strongly focused pipeline and clinical development

- Focused early-stage pipeline for value creation
- Opportunities to broaden into other cancer indications

Run by seasoned leadership team

- Leadership team with a clear track record
- Best in class Clinical Advisory Board

Multiple value inflection points over the next few years